Jubilant Pharmova Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova's wholly-owned step-down subsidiary, Jubilant Generics Limited (JGL), received a tax order from the Income Tax Department dated May 21, 2026 for FY23. The order involves transfer pricing adjustments of Rs. 107.89 crores, which the company claims ignores its facts and contentions. JGL plans to file appeals before the Commissioner of Income Tax (Appeals) and has also filed a separate application before the Advance Pricing Authority. The company expects the adjustments to be deleted after adjudication and does not anticipate material financial implications. However, the order may reduce Deferred Tax Assets by Rs. 37.70 crores.
While the company expects relief on appeal, the Rs. 107.89 crore tax adjustment and Rs. 37.70 crore reduction in Deferred Tax Assets could create near-term earnings pressure and negative sentiment, especially if the legal outcome is unfavorable.